Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular, Molecular, and Tumor Biology 91: Receptor Tyrosine Kinase Signaling

IGFBP4 inhibits IGF1 driven tumour cell proliferation and VEGF expression

Anthony J. Ryan, Dermot Mc Brierty, David Bouchier-Hayes and Judith H. Harmey
Anthony J. Ryan
Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dermot Mc Brierty
Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Bouchier-Hayes
Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith H. Harmey
Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

4339

Insulin like growth factors (IGFs) play key roles in growth, development, cellular transformation and survival of malignant cells. Bioavailability of IGFs is regulated by the IGF binding proteins (IGFBPs), which bind IGFs. IGF release is dependent on cleavage of the IGFBPs by their proteases. There is conflicting data on the significance of IGF and IGFBP expression in tumour growth. We examined the expression of IGFBP4 and its recently identified protease pregnancy associated plasma protein A (PAPP-A), in normal and tumour mouse tissues and 4T1.2 mammary adenocarcinoma cells by Western blotting. The effects of wild type IGF1 and recombinant mutant IGF1, which is resistant to IGFBP binding (IGF1(RE)), were examined on proliferation of 4T1.2 cells. 4T1.2 cells over express IGFBP4 but not PAPP-A. IGF1 at of 50, 100, 500, 1000, and 2000ng/ml did not stimulate proliferation of 4T1.2 cells whereas IGF1 (RE) at 50, 100, 500, 1000, and 2000ng/ml, increased proliferation of these cells (p< 0.05 ANOVA with LSD post hoc). In normal tissues, intact IGFBP4 expression was highest in brain tissue, which did not express PAPP-A. In normal spleen, liver, lung, heart, skin and kidney high levels of PAPP-A were expressed and IGFBP4 was either present at very low levels or completely absent. In 4T1.2 mammary fat pad tumours, lung and bone metastases, the pattern of intact IGFBP4 was the inverse of PAPP-A expression. These data show that IGFBP4-resistant IGF1 stimulates tumour cell proliferation whereas IGF1 bound by IGFBP4 does not. Furthermore, intact IGFBP4 is only present in tissues where PAPP-A is absent. Our results suggest that PAPP-A regulates IGF1 bioactivity via cleavage of IGFBP4. It has been shown in tumour cells that IGF1 increases the expression of VEGF. IGF1 had no effect on VEGF expression of 4T1.2 cells (≥ 50 ng/ml) increased VEGF expression. Our data suggests that IGFBP4 inhibits IGF1 driven tumour cell proliferation and VEGF production. However in vivo IGFBP4 cleavage by PAPP-A, releases bioactive IGF1. Therefore development of a protease-resistant IGFBP4 or inhibiting production of PAPP-A, may be of therapeutic value in blocking the activity of IGF1 in breast cancer Funded by the Irish Cancer Society/ Cancer Research Ireland

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IGFBP4 inhibits IGF1 driven tumour cell proliferation and VEGF expression
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
IGFBP4 inhibits IGF1 driven tumour cell proliferation and VEGF expression
Anthony J. Ryan, Dermot Mc Brierty, David Bouchier-Hayes and Judith H. Harmey
Cancer Res April 1 2004 (64) (7 Supplement) 1001-1002;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IGFBP4 inhibits IGF1 driven tumour cell proliferation and VEGF expression
Anthony J. Ryan, Dermot Mc Brierty, David Bouchier-Hayes and Judith H. Harmey
Cancer Res April 1 2004 (64) (7 Supplement) 1001-1002;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Proteomic analysis of transgenic mice with constitutive overexpression of insulin-like growth factor 1 in epidermal basal cells
  • IGF-1R ubiquitination: A new dimension in IGF-1 signaling pathways
  • Effects of insulin-like growth factor-binding proteins 1 through 5 on in vitro angiogenesis assay
Show more Cellular, Molecular, and Tumor Biology 91: Receptor Tyrosine Kinase Signaling
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement